Delving into the Latest Updates on AB-110 with Synapse

Overview

Basic Info

Drug Type

Gene therapy, Stem cell therapy

Synonyms

Target-

Mechanism

Cell replacements

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic Neoplasms

Inactive Indication

acute leukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+ [1]

Originator Organization

Angiocrine Bioscience, Inc.

Active Organization

Yinfeng Biological Engineering Group Co. Ltd.

Inactive Organization

Angiocrine Bioscience, Inc.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).

Start Date24 Apr 2018

Sponsor / Collaborator

Angiocrine Bioscience, Inc.

[+1]

JPRN-jRCT2080222230 / Unknown statusPhase 3

A Phase III, Randomized, Double-blind, Active-controlled 12 week Study Evaluating the Efficacy and Safety of KRP-AB1102F DPI Compared with KRP-AB1102 DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Start Date24 Sep 2013

Sponsor / Collaborator

KYORIN Pharmaceutical Co., Ltd.

JPRN-JapicCTI-132224 / Unknown statusPhase 3

A Phase III, Open-label, 52week Study Evaluating the Safety and Efficacy of KRP-AB1102F DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Start Date01 Sep 2013

Sponsor / Collaborator

KYORIN Pharmaceutical Co., Ltd.

100 Clinical Results associated with AB-110

Login to view more data

100 Translational Medicine associated with AB-110

Login to view more data

100 Patents (Medical) associated with AB-110

Login to view more data

2

Literatures (Medical) associated with AB-110

01 Sep 2011·Antiviral ResearchQ2 · MEDICINE

Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus

Q2 · MEDICINE

Article

Author: Masaya Takemoto ; Aishun Jin ; Atsushi Muraguchi ; Kimiyasu Shiraki ; Hiroyuki Kishi ; Tatsuhiko Ozawa ; Tomoko Okuda ; Kazuto Tajiri

The extra-cellular domain of the influenza virus matrix protein 2 (M2e) is highly conserved between influenza A virus strains compared to hemagglutinin and neuraminidase, and has long been viewed as a potential and universal vaccine target. M2e induces no or only weak and transient immune responses following infection, making it difficult to detect M2e-specific antibodies producing B-cells in human peripheral blood lymphocytes. Recently, using a single-cell manipulation method, immunospot array assay on a chip (ISAAC), we obtained an M2e-specific human antibody (Ab1-10) from the peripheral blood of a healthy volunteer. In this report, we have demonstrate that Ab1-10 reacted not only to seasonal influenza A viruses, but also to pandemic (H1N1) 2009 virus (2009 H1N1) and highly pathogenic avian influenza A virus, and that the antibody-bound M2e of 2009 H1N1 inactivated the virus with high affinity (∼10(-10)M). More importantly, it inhibited 2009 H1N1 viral propagation in vitro. These results suggest that Ab1-10 might be a potential candidate for antibody therapeutics for a wide range of influenza A viruses.

01 Jan 1988·The Journal of AntibioticsQ4 · MEDICINE

A novel naturally occurring carbapenem antibiotic, AB-110-D, produced by Kitasatosporia papulosa novo sp.

Q4 · MEDICINE

Article

Author: Ono, Eiji ; Shibai, Hiroshiro ; Ishii, Koichi ; Yokogawa, Yasunori ; Kohda, Toru ; Nakamura, Yoshihiro ; Ishihara, Masaru

AB-110D (I) was isolated from the culture filtrate of K. papulosa by anion-exchange chromatog. on Diaion SA20A followed by repeated chromatog. on QAE-Sephadex A-25 and Diaion SP-207.These procedures separated I from the related antibiotics epithienamycins A, B, E, and F.The physicochem. properties and mol. structure of I were established.I exhibited a strong antimicrobial activity against gram-pos. and gram-neg. bacteria and was highly stable to β-lactamases (penicillinase and cephalosporinase).

100 Deals associated with AB-110

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 2	US	Angiocrine Bioscience, Inc.	24 Apr 2018
Hematologic Neoplasms	Phase 1	CN	Yinfeng Biological Engineering Group Co. Ltd.	-
acute leukemia	Discovery	US	Angiocrine Bioscience, Inc.	24 Apr 2018
Acute Myeloid Leukemia	Discovery	US	Angiocrine Bioscience, Inc.	24 Apr 2018
Myelodysplastic Syndromes	Discovery	US	Angiocrine Bioscience, Inc.	24 Apr 2018